
New Phase 3 data has been released showing that both 50mg and 100mg doses of Allergan’s ubrogepant met their primary …

Allergan has revealed positive Phase 3 data on its oral calcitonin gene-related peptide (CGRP) receptor antagonist ubrogepant, illustrating the therapy’s …

Allergan has revealed new data from the second of two Phase 3 studies into the efficacy of its calcitonin gene-related …

